Intracardiac adenosine triphosphate for cardioversion of supraventricular tachycardia in a hydropic foetus: a case report Authors: Junhui Liu, Gang Luo, Yue Sun, Yan Xu, Silin Pan Published: 2026 ABSTRACT AbstractBackgroundFoetal supraventricular tachycardia (SVT) can cause foetal hydrops and demise if untreated. Transplacental therapy often fails in severe SVT with foetal hydrops due to impaired placental drug transfer. In the present study, we report the first successful cardioversion of recalcitrant SVT in a hydropic foetus by intracardiac adenosine triphosphate (ATP) administration.Case summaryA 34-year-old woman at 28 + 6 weeks of gestation was admitted for persistent foetal tachycardia, subsequently diagnosed as foetal SVT. After combined transplacental therapy with digoxin and sotalol, the foetal tachycardia remained uncontrolled, with progressive hydrops and deteriorating cardiac function. Ultimately, intracardiac ATP administration was performed and achieved successful cardioversion of the foetal SVT. No procedure-related complications occurred. After the procedure, maternal oral digoxin and sotalol were continued to maintain foetal sinus rhythm.DiscussionIntracardiac ATP administration offers a last-resort salvage therapy for terminating recalcitrant SVT with foetal hydrops, which should be reserved for highly selected patients and performed at specialized centres. The larger studies with longer follow-up are needed to validate this procedure’s efficacy and safety. Intracardiac ATP administration is a last-resort salvage therapy for highly selected foetal SVT cases with failed transplacental therapy and imminent foetal demise. Intracardiac ATP administration is a last-resort salvage therapy for highly selected foetal SVT cases with failed transplacental therapy and imminent foetal demise. Intracardiac ATP administration should only be performed in specialized centres with extensive foetal cardiac intervention and multidisciplinary collaboration experience. Intracardiac ATP administration should only be performed in specialized centres with extensive foetal cardiac intervention and multidisciplinary collaboration experience. Introduction Foetal tachyarrhythmias occur in approximately 0.5% of pregnancies and represent a critical cardiac emergency. Supraventricular tachycardia (SVT) is the most common type. Untreated tachycardia can lead to heart failure, hydrops, preterm delivery, and foetal demise.1 Studies show that 30%–40% of foetuses with severe SVT develop hydrops if untreated, increasing the risk of demise.2,3 First-line therapy for foetal SVT involves transplacental administration of antiarrhythmics such as digoxin, flecainide, or sotalol. Combination therapy is often required in hydropic cases.1 For refractory cases, direct foetal therapy (intramuscular, intraperitoneal, intra-amniotic, intracardiac, or umbilical vein) may be necessary to achieve successful cardioversion.1 Adenosine triphosphate (ATP) is well established for acute termination of SVT across all ages due to its rapid onset, and its ultra-short half-life allows for safe repeat administration.4 Evidence on direct foetal ATP administration is currently limited to the umbilical vein route.5,6 To date, no study has reported direct intracardiac ATP administration for foetal SVT. Here, we report the first successful cardioversion of recalcitrant foetal SVT via intracardiac ATP injection. We detail the procedure, including pre-procedural evaluation, ultrasound-guided cardiac puncture, intracardiac ATP injection, and post-procedural management, to provide clinical insights for managing similar complex cases. Summary figure Case presentation A 34-year-old woman was admitted at 28 + 6 weeks’ gestation for foetal tachycardia. Foetal echocardiography confirmed an initial diagnosis of SVT at 234 b.p.m. (Figure 1A), with moderate tricuspid and mild mitral regurgitation. Ultrasound revealed abdominal effusion (maximal depth 1.8 cm), and the foetal cardiovascular profile score (CVPS) was 7. Following clinical expert guidance,7 maternal oral digoxin (0.25 mg every 8 h) was initiated 1 day after admission. Therapeutic maternal levels were achieved after 72 h, but foetal heart rate (FHR) showed no significant reduction, and abdominal effusion worsened (maximal depth 3.3 cm). Sotalol was then added, starting at 80 mg every 12 h and gradually increased to 160 mg every 12 h. After 12 days of combined therapy, foetal tachycardia persisted with progressive hydrops (Figure 1B and C), including worsening pleural, pericardial, and abdominal effusions, and deteriorating cardiac function. The cardiothoracic ratio increased to 0.35, and CVPS dropped to 5, indicating imminent foetal demise. Given failed transplacental therapy, rapid hydrops progression, and cardiac function deterioration, a salvage approach combining right atrial ‘physical pacing’ and intracardiac ATP administration was proposed. After careful risk–benefit counselling, the patient consented to the procedure. Pre-procedural foetal assessment. (A) Foetal echocardiography demonstrates supraventricular tachycardia at 234 b.p.m. with 1:1 atrioventricular conduction. Foetal ultrasound shows foetal hydrops with pericardial, pleural (B), and abdominal effusion (C). Initially, the foetus was in a prone position, with the right atrium deep and inaccessible from the maternal abdominal wall. Gentle manual manipulation was performed to reposition the foetus, making the right atrium adjacent to the abdominal wall. Under maternal general anaesthesia, a 22-gauge, 150-mm puncture needle (Terumo Corporation) was advanced under ultrasound guidance through the maternal abdominal wall, uterine wall, amniotic cavity, and foetal chest wall into the foetal right atrium (Figure 2). A 0.014-inch coronary guidewire (Abbott Vascular) was introduced to stimulate the right atrial endocardium for 15 s, based on the principle of ‘overdrive suppression’, but it failed to terminate the tachycardia (Video 1). The ATP dosage of 0.2 mg/kg was determined based on prior experience with foetal SVT treatment via the umbilical vein route5,8,6 and neonatal clinical practice.9 The estimated foetal weight was 1.5 kg. Therefore, under ultrasound guidance, 0.3 mg of ATP was injected into the foetal right atrium, followed by a 0.5 ml saline flush. This immediately terminated foetal tachycardia but FHR decreased to 80 b.p.m. (Video 2). To address the bradycardia, 0.2 mg of atropine was injected into the foetal right atrium through the established cardiac route and increased the FHR to 180 b.p.m. (Video 2). The needle was then withdrawn into the amniotic cavity, and 30 ml of amniotic fluid was aspirated for whole-genome sequencing (WGS). No maternal and foetal adverse events occurred. Ultrasound-guided intracardiac puncture. The foetal right atrium is positioned adjacent to the maternal abdominal wall via gentle manual manipulation. A 22-gauge, 150-mm puncture needle is advanced through the maternal abdominal wall, uterine wall, amniotic cavity, and foetal chest wall into the foetal right atrium under ultrasound guidance. After the procedure, maternal oral digoxin and sotalol were continued, and foetal sinus rhythm was maintained at 150–160 b.p.m. WGS identified a de novo heterozygous nonsense variant in the foetus: NM_001754.5(RUNX1):c.1271C>A (p.Ser424Ter), which is predicted to cause haematologic disorders. Following genetic counselling and multidisciplinary consultation, the couple opted for pregnancy termination, which was carried out at 32 + 4 weeks’ gestation. Discussion Foetal SVT represents a clinical emergency, and prompt treatment is mandatory.8 In the present study, we report the first successful cardioversion of recalcitrant SVT in a hydropic foetus by intracardiac ATP administration after failed transplacental therapy, providing a salvage therapy for the recalcitrant foetal SVT. Although transplacental therapy is highly effective for foetal SVT, its success is often limited in hydropic foetuses due to placental oedema impairing drug transfer.10,11 In the present case, after 15 days of failed transplacental therapy, the foetal CVPS dropped to 5, indicating imminent foetal demise. Given that compromised circulation would also hinder the transfer of alternative antiarrhythmics (e.g. flecainide or amiodarone),12 and that any delay in achieving therapeutic foetal concentrations would increase the risk of demise, we performed direct foetal therapy to achieve rapid cardioversion of foetal SVT. ATP is highly effective for emergency cardioversion of SVT across all ages.9 It is rapidly hydrolysed to adenosine, which induces sinus slowing via adenosine receptors.13 Its ultra-short half-life allows for safe repeat administration, and as an endogenous nucleoside, it poses minimal risk to the mother and fetus.13 Literature on direct foetal ATP administration for SVT is limited to the umbilical vein route.5,8,6 However, in severe hydrops, compromised circulation would hinder drug delivery from the umbilical vein to the heart, reducing efficacy and complicating dosing. Intramuscular ATP administration is similarly limited by unpredictable absorption and lack of foetal evidence.14 In contrast, intracardiac administration ensures immediate, precise drug delivery to the target tissue and allows for prompt resuscitation if complications arise. Importantly, this approach was supported by our team’s extensive experience in foetal cardiac intervention and multidisciplinary collaboration.15 However, ATP does not prevent the recurrence of SVT due to its short half-life. Following successful cardioversion, maternal oral digoxin and sotalol were continued to maintain sinus rhythm in our case, consistent with previous reports.5,8,6 Post-procedural foetal echocardiography is recommended once or twice weekly. If SVT recurs, strategies, including transplacental, intracardiac, umbilical vein, or intramuscular therapy, should be reassessed based on gestational age, hydrops status, and medication response. If necessary, caesarean delivery may also be considered for postnatal management of SVT. Intracardiac administration is invasive, with risks and management strategies including: (i) Cardiac perforation/tamponade: managed by real-time ultrasound guidance and pericardiocentesis if needed. (ii) Severe bradycardia/cardiac arrest: resuscitation drugs (e.g. atropine or epinephrine) must be prepared in advance, with emergency caesarean section available. (iii) Foetal distress/demise: obstetrics and neonatology teams should be ready for emergency delivery. (iv) Maternal complications: anaesthesia-related risks, bleeding, infection, and organ injury, managed by experienced anaesthesia and obstetrics teams. Contraindications of this procedure include foetal sinus node dysfunction, atrioventricular block, atrial/ventricular tachycardia,13 low foetal weight or early gestational age, unfavourable foetal position, active maternal infection, or coagulation disorders. Therefore, this approach should be reserved for highly selected cases meeting all criteria: (i) failure of standard transplacental therapy with at least two antiarrhythmic agents. (ii) Progressive foetal hydrops with imminent intrauterine demise. (iii) Alternative direct foetal routes (e.g. umbilical vein or intramuscular) are suboptimal due to pharmacokinetic limitations or other conditions. Notably, this procedure should be performed at a specialized centre with experience in foetal cardiac interventions and multidisciplinary collaboration. Dangel et al.8 emphasize that early intervention of foetal SVT is critical, as prolonged hypoxia from foetal SVT may cause irreversible brain injury. Studies indicated that in the early course of disease, before severe hydrops develops, umbilical vein administration may be a safer, more feasible option.5,8,6 In this case, umbilical vein administration could be cautiously considered as an alternative treatment when digoxin therapy proved ineffective and before the progression to severe hydrops. Although fetoscopic transoesophageal pacing has been reported to be effective for terminating recalcitrant foetal SVT,16,17 it was not adopted in our study due to the procedural complexity, the unfavourable foetal position, and the concern that pleural or pericardial effusions could limit the pacing efficacy. The failure of physical pacing warrants further analysis. While inducing a premature beat via endocardial stimulation is theoretically plausible, practical limitations, such as delivering an effective mechanical stimulus in a dynamic, blood-filled chamber and achieving reliable cardiomyocyte depolarization, pose significant challenges. Future research may explore smaller catheter ablation via foetal cardiac puncture. In conclusion, intracardiac ATP administration serves as a last-resort therapy for terminating recalcitrant foetal SVT. Its safety and feasibility require further validation.